Immunomodulatory effect of fructose-1,6-bisphosphate on T-lymphocytes

Int Immunopharmacol. 2003 Feb;3(2):267-72. doi: 10.1016/S1567-5769(02)00295-3.

Abstract

Sepsis remains an important and life-threatening problem, and is the most common cause of death in the intensive care unit. One promising therapeutic candidate for protection against injury in sepsis is fructose-1,6-bisphosphate (FBP), a high-energy glycolytic pathway intermediate. The objective of the study was to establish a role for FBP on the immune system, especially in lymphocyte proliferation. Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy humans by gradient centrifugation. T-lymphocytes were stimulated for 96 h with phytohemagglutinin (PHA) and varying concentration of FBP. Fructose-1,6-bisphosphate at concentrations between 1.2 and 10 mM decreased proliferation of T-lymphocytes and reduced the viability only at concentrations 5.0 and 10 mM. The levels of soluble IL-2 receptor were reduced at FBP concentrations between 1.2 and 10 mM. In conclusion, this study demonstrates that FBP has important effect on immunomodulatory and this result can be correlated with the protection against injury in sepsis.

MeSH terms

  • Calcium / metabolism
  • Cell Survival / drug effects
  • Fructosediphosphates / pharmacology*
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Lymphocyte Activation / drug effects*
  • Receptors, Interleukin-2 / analysis
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology

Substances

  • Fructosediphosphates
  • Immunosuppressive Agents
  • Receptors, Interleukin-2
  • fructose-1,6-diphosphate
  • Calcium